Phase I Study of Anti-CD22 CAR T Cells for Hairy Cell Leukemia
This study is testing a new treatment called CD22CART cell infusion for adults with hairy cell leukemia (HCL) or hairy cell leukemia variant (HCLv) that has come back or hasn't responded to other treatments. CD22CART cell infusion is a type of immunotherapy where your own immune cells (T cells) are specially trained to find and fight cancer cells. Before receiving the CD22CART cells, you would have a short course of chemotherapy. Researchers want to see if this treatment is safe and how well it works to shrink the cancer. You may be eligible if you are 18 or older and have HCL or HCLv that meets certain criteria, such as low blood counts or an enlarged spleen.
- Study design
- This is a Phase I interventional study aiming to enroll 27 participants. It will test the safety and effectiveness of CD22CART cell infusion.
- What's involved
- The treatment involves lymphodepleting chemotherapy followed by a CD22CART infusion. Specific details about visits or other procedures are not specified.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for the anti-tumor effect of the treatment every year for 15 years after the end of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04815356
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Recruiting
PHASE1Ages 18+InterventionalTreatmentNational Cancer Institute (NCI)Government-funded
~27 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:CD22CART cell infusion
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
safety and feasibility
Measured over end of treatment
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- Robert J Kreitman, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed diagnosis of HCL or HCLv according to morphological and immunophenotypic criteria of WHO classification \[WHO, 2008 revised 2016\] of lymphoid neoplasm.
Participants should have any of the following indications for therapy:
ANC \<1/nL,
Hemoglobin \<10g/dL,
Platelets\<100/nL,
Symptomatic splenomegaly,
HCL mass with short axis \> 2 cm outside or \>0.5 cm inside the CNS,
HCL/HCLv count \>5/nL in blood or \>25/mm\^3 in CSF,
HCL/HCLv count doubling time \<6 months and increasing lytic or blastic bone lesions
HCL/HCLv, after prior treatment with, ineligible for, refusal of, or inability to obtain 1)rituximab given concurrently with or sequentially after purine analog, 2) moxetumomab pasudotox-tdft, and 3) BRAF-inhibition.
CD22 expression must be detected on greater than 80% of malignant cells by flow cytometry.
Participants must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease (MRD) detected by flow cytometry or immunohistochemistry.
Age \>=18 years
ECOG performance \<=2 (Karnofsky \>=60%, see Appendix A), participants are exempt from this criterion if poor performance status is related to HCL.
Participants must have adequate organ function as defined below: Participants must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met. If participants exhibit minor lab abnormalities that are determined to be related to HCL (not therapy-related), then those participants will be allowed to participate
Total bilirubin \<= 3 ULN, unless consistent with Gilbert s (ratio between total and direct bilirubin \> 5)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<= 3x upper limit of normal (ULN)
Alkaline phosphatase \< 2.5 ULN
Serum creatinine \<= 1.5 mg/dL or creatinine clearance \>= 60 mL/min/1.73 m\^2 for participants with creatinine levels above institutional normal calculated using eGFR or measured
Serum albumin \> 2 g/dL
Prothrombin time (PT)/International Normalized Ratio (INR) \< 2.5x ULN (if on warfarin, PT/INR \< 3.5x ULN; If on any other anticoagulation, PT \< 2.5x ULN
Fibrinogen \>= 0.5x lower limit of normal
Participants with CNS disease are eligible, with exceptions
Participants with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active graft-versus-host disease (GVHD) and no longer taking immunosuppressive agents for at least 30 days prior to initiation of study intervention.
Women of childbearing potential (WOCBP) must agree to use effective contraception (barrier, hormonal, intrauterine device \[IUD\], abstinence, surgical sterilization) at the study entry and up to 12 months after the last dose of combined chemotherapy or 4 months after cells infusion, whichever is later.
Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 4 months after the last dose of study drug.
Ability of participant to understand and the willingness to sign a written informed consent document.
Exclusion
Pregnancy
Systemic chemotherapy, immunotherapy, or radiation therapy \<= 2 weeks prior to apheresis with the following exception:
Participants receiving steroids may be enrolled, provided there has been no increase in dose for at least 1 week prior to starting apheresis;
For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the participant has measurable/evaluable disease outside the radiation port.
Other anti-neoplastic investigational agents, or antibody-based therapies currently or within 2 weeks prior to apheresis
Participants taking warfarin
Prior CAR therapy within 30 days prior to apheresis or prior CAR therapy at any time with evidence for persistence of CAR T cells in blood samples (circulating levels of genetically modified cells of \>= 5% by flow cytometry)
Seropositive for human immunodeficiency virus (HIV) antibody. (Participants with HIV are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy in the future should study results indicate effectiveness.)
Seropositive for hepatitis C virus (HCV) or positive for hepatitis B surface antigen (HbsAG). Participants who convert to negative will not be excluded for history of positive test.
Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, asthma, chronic obstructive pulmonary disease, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e., gentamicin)
What this trial measures
- safety and feasibilityend of treatment
Fraction of participants at each dose level who experience a toxicity along with the grades and types of toxicity and which can successfully manufacture the targeted dose number
- antitumor effectevery year for 15 years
The fraction of participants who experience a CR among the 10 evaluable participants treated at the MTD or highest safe dose